Charline Faville

May 2, 2024 | biorxiv.org | Bianca Silva |Frédéric Baron |Grégory Ehx |Charline Faville

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) is the main therapeutic approach for patients with high-risk acute myeloid leukemia (AML), but the rate of relapse remains high and is associated with poor outcomes. Discovering new approaches to maximize the graft-versus-leukemia (GVL) effects while mitigating graft-versus-host disease (GVHD) should therefore be pursued.